Browsing by Author "Arribas, Joaquín"

Sort by: Order: Results:

  • Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
    Arenas, Enrique J.; Martínez Sabadell, Alex; Rius Ruiz, Irene; Román Alonso, Macarena; Escorihuela, Marta; Luque, Antonio; Fajardo, Carlos Alberto; Gros, Alena; Klein, Christian; Arribas, Joaquín (Nature Research, 2021)
    Immunotherapy has raised high expectations in the treatment of virtually every cancer. Many current efforts are focused on ensuring the efficient delivery of active cytotoxic cells to tumors. It is assumed that, once these ...
  • Epstein-Barr virus+ B cells in breast cancer immune response: a case report
    Aran, Andrea; Peg, Vicente; Rabanal, Rosa María; Bernadó, Cristina; Zamora, Esther; Molina, Elisa; Arribas, Yago A.; Arribas, Joaquín; Pérez, José; Roura-Mir, Carme; Carrascal, Montserrat; Cortés, Javier; Martí, Mercè (Frontiers, 2021)
    EBV-specific T cells have been recently described to be involved in fatal encephalitis and myocarditis in cancer patients after immune checkpoint therapies. Here, we report the study of a human triple-negative breast cancer ...
  • Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation
    Gámez-Chiachio, Manuel; Molina-Crespo, Ángela; Ramos-Nebot, Carmen; Martinez-Val, Jeannette; Martinez, Lidia; Gassner, Katja; Llobet, Francisco J.; Soriano, Mario; Hernandez, Alberto; Cordani, Marco; Bernadó Morales, Cristina; Diaz, Eva; Rojo-Sebastian, Alejandro; Triviño Salazar, Juan Carlos; Sánchez, Laura; Rodríguez-Barrueco, Ruth; Arribas, Joaquín; Llobet-Navás, David; Sarrió, David; Moreno-Bueno, Gema (BioMed Central, 2022)
    Background: Gasdermin B (GSDMB) over-expression promotes poor prognosis and aggressive behavior in HER2 breast cancer by increasing resistance to therapy. Decoding the molecular mechanism of GSDMB-mediated drug resistance ...
  • GDF15 is an eribulin response biomarker also required for survival of DTP breast cancer cells
    Bellio, Chiara; Emperador, Marta; Castellano, Pol; Gris-Oliver, Albert; Canals, Francesc; Sánchez Pla, Alexandre; Zamora¸ Esther; Arribas, Joaquín; Saura, Cristina; Serra, Violeta; Tabernero Cartula, Josep; Littlefield, Bruce A.; Villanueva, Josep (MDPI, 2022)
    Drug tolerant persister (DTP) cells enter into a reversible slow-cycling state after drug treatment. We performed proteomic characterization of the breast cancer (BC) DTP cell secretome after eribulin treatment. We showed ...
  • High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
    Palafox, Marta; Gonzalez-Perez, Abel; Arribas, Joaquín; López Bigas, Núria; Serra, Violeta (Nature Research, 2022)
    CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are ...
  • LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer
    Pérez-Núñez, Iván; Rozalén, Catalina; Palomeque, José Ángel; Sangrador, Irene; Dalmau, Mariona; Comerma Blesa, Laura, 1983-; Hernández Prat, Anna, 1984-; Casadevall Aguilar, David; Menendez Romero, Silvia; Liu, Daniel Dan; Berenguer De Felipe, Jordi; Peña Arranz, Raúl, 1976; Montañés, José Carlos; Albà Soler, Mar; Bonnin, Sarah; Ponomarenko, Julia; Servitja Tormo, Sonia; Arribas, Joaquín; Albanell Mestres, Joan; Celià-Terrassa, Toni (Nature Research, 2022)
    Ligand-dependent corepressor (LCOR) mediates normal and malignant breast stem cell differentiation. Cancer stem cells (CSCs) generate phenotypic heterogeneity and drive therapy resistance, yet their role in immunotherapy ...
  • LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells
    Cebrià i Costa, Joan Pau, 1989-; Pascual-Reguant, Laura; Gonzalez-Perez, Abel; Serra Bardenys, Gemma, 1992-; Querol, J.; Cosín, M.; Verde, Gaetano; Cigliano, Riccardo Aiese; Sanseverino, Walter; Segura-Bayona, Sandra; Iturbide Martínez de Albéniz, Ane, 1989-; Andreu Martínez, David; Nuciforo, Paolo G.; Bernado-Morales, C.; Rodilla, Verónica; Arribas, Joaquín; Yélamos López, José; García de Herreros, Antonio; Stracker, Travis; Peiró Sales, Sandra (Nature Research, 2020)
    Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) ...
  • Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
    Mateo, Lidia; Duran-Frigola, Miquel, 1985-; Gris-Oliver, Albert; Palafox, Marta; Scaltriti, Maurizio; Razavi, Pedram; Chandarlapaty, Sarat; Arribas, Joaquín; Bellet, Meritxell; Serra, Violeta; Aloy, Patrick, 1972- (BioMed Central, 2020)
    Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence ...
  • Protocol to generate a patient derived xenograft model of acquired resistance to immunotherapy in humanized mice
    Martínez Sabadell, Alex; Ovejero Romero, Pablo; Arribas, Joaquín; Arenas, Enrique J. (Elsevier, 2022)
    Immunotherapy has revolutionized cancer treatment, but preclinical models are required to understand immunotherapy resistance mechanisms underlying patient relapse. This protocol describes how to generate an acquired ...
  • Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
    Adam-Artigues, Anna; Rovira Guerín, Ana; Albanell Mestres, Joan; Arribas, Joaquín; Cejalvo, Juan M. (American Association for the Advancement of Science (AAAS), 2022)
    Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of ...
  • TGFβ-activated USP27X deubiquitinase regulates cell migration and chemoresistance via stabilization of snail1
    Lambies Barjau, Guillem, 1990-; Miceli, Martina; Martínez-Guillamon, Catalina; Olivera-Salguero, Rubén; Peña, Raúl; Frías, Carolina-Paola; Calderón, Irene; Atanassov, Boyko S.; Dent, Sharon Y.R.; Arribas, Joaquín; García de Herreros, Antonio; Díaz Cortés, Víctor Manuel, 1956- (American Association for Cancer Research (AACR), 2019)
    In cancer cells, epithelial-to-mesenchymal transition (EMT) is controlled by Snail1, a transcriptional factor also required for the activation of cancer-associated fibroblasts (CAF). Snail1 is short-lived in normal epithelial ...
  • The target antigen determines the mechanism of acquired resistance to T cell-based therapies
    Martínez Sabadell, Alex; Morancho Armisen, Beatriz; Rius Ruiz, Irene; Román Alonso, Macarena; Ovejero Romero, Pablo; Escorihuela, Marta; Chicote, Irene; Palmer, Héctor G.; Nonell Mazelon, Lara, 1972-; Alemany-Chavarria, Mercè; Klein, Christian; Bacac, Marina; Arribas, Joaquín; Arenas, Enrique J. (Elsevier, 2022)
    Despite the revolution of immunotherapy in cancer treatment, patients eventually progress due to the emergence of resistance. In this scenario, the selection of the tumor antigen can be decisive in the success of the ...
  • Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer
    Duro-Sánchez, Santiago; Nadal-Serrano, Mercedes; Lalinde-Gutiérrez, Marta; Arenas, Enrique J.; Bernadó Morales, Cristina; Morancho Armisen, Beatriz; Escorihuela, Marta; Pérez-Ramos, Sandra; Escrivá-de-Romaní, Santiago; Gandullo-Sánchez, Lucía; Pandiella, Atanasio; Esteve-Codina, Anna; Rodilla, Verónica; Dijcks,Fred A.; Dokter, Wim H.A.; Cortés, Javier; Saura, Cristina; Arribas, Joaquín (American Association for Cancer Research (AACR), 2022)
    Antibody-drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive ...